NY-SIMPSON-THACHER
5.9.2022 09:01:35 CEST | Business Wire | Press release
Simpson Thacher & Bartlett LLP announced today that Sarah Lindley has joined the Firm as a Partner in its London office where she will be a part of its global Tax Practice.
“Known for advising a wide range of clients on their most significant, complex transactions, Sarah is recognized as one of the preeminent tax advisors in Europe, and we are delighted to welcome her to Simpson Thacher,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “She has a distinct blend of tax expertise that will be tremendously beneficial to our clients, particularly as international tax principles continue to evolve to address macroeconomic changes, such as an increasingly digital economy, as well as geopolitical developments, such as Brexit.”
Previously a partner in Linklaters’ Tax Practice, Sarah advises a variety of clients on tax aspects across the full spectrum of corporate transactions, including mergers and acquisitions, dispositions and asset sales, corporate restructurings and tax planning. In particular, she has advised numerous clients across the technology and financial services sectors. Sarah also has significant experience in the areas of finance tax and contentious tax.
“Sarah has extensive experience providing some of Europe’s most prominent companies and financial institutions with exceptional tax advice related to complex and strategic transactions,” said London office Managing Partner Jason Glover. “Sarah is a perfect complement to our best-in-class team of U.K. and U.S.-trained tax lawyers, who make up our London-based Tax team.”
Yash Rupal, Head of the Firm’s U.K. Tax Practice, noted, “Sarah is known in the market for providing clients with creative, commercial advice on U.K. tax issues amidst changing laws and heightened scrutiny by authorities. We are all very excited to have Sarah join our growing London-based Tax group.”
“Simpson Thacher has a preeminent global Tax Practice that is unparalleled in its solutions-oriented, value-add approach to client advice,” said Sarah. “The Firm’s collegial environment and the opportunity to work with its world-class lawyers across all of its practices was very attractive to me and I am thrilled to be joining the team.”
Simpson Thacher’s Tax Practice is continuously called upon by multinational corporations, banks, investment funds and other leading companies for advice on their largest and most complex transactions. The global team works closely with colleagues in the Firm’s Mergers and Acquisitions, Private Equity, Capital Markets, Private Funds and Real Estate Practices, among others, to offer clients the full spectrum of deal and fund capabilities.
For more than four decades, Simpson Thacher’s London office has advised a diverse roster of clients on their most significant transactions and legal matters throughout Europe. The London office has grown markedly in recent years—now home to approximately 200 lawyers—including several recent high-profile partner additions across its Antitrust, Investment Funds and Funds Regulatory, Private Equity, Real Estate, Restructuring and Tax Practices.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220904005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
